Genprex (GNPX) Accounts Payables (2016 - 2026)
Genprex (GNPX) posted quarterly Accounts Payables of $1.7 million for Q1 2026, up 8.48% year-over-year from $1.5 million in Q1 2025, and up 122.73% quarter-over-quarter from $743070.0 in Q4 2025.
Genprex (GNPX) Accounts Payables (2016 - 2026) Analysis & Trends
Genprex's Accounts Payables history runs 11 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 8.48% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 8.48% YoY), while the FY2025 annual figure was $743070.0, down 30.83% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.7 million, up from $743070.0 in the prior quarter.
- The five-year high for Accounts Payables was $2.2 million in Q1 2023, with the low at $442925.0 in Q4 2022.
- The 5-year median for Accounts Payables is $1.3 million (2022), against an average of $1.3 million.
- Peak annual rise in Accounts Payables reached 269.64% in 2022, while the deepest fall reached 54.49% in 2022.
- Genprex's Accounts Payables stood at $442925.0 in 2022, then jumped by 215.54% to $1.4 million in 2023, then fell by 23.13% to $1.1 million in 2024, then slumped by 30.83% to $743070.0 in 2025, then jumped by 122.73% to $1.7 million in 2026.
- Business Quant data shows GNPX's Accounts Payables at $1.7 million in Q1 2026, $743070.0 in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | 293,579.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.66 Mn |
| Dec 31, 2025 | 743,070.00 |
| Sep 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 930,812.00 |
| Mar 31, 2025 | 1.53 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.17 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 1.18 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 2.21 Mn |
| Dec 31, 2022 | 442,925.00 |
| Sep 30, 2022 | 683,871.00 |
| Jun 30, 2022 | 683,323.00 |
| Mar 31, 2022 | 1.25 Mn |
| Dec 31, 2021 | 973,195.00 |
| Sep 30, 2021 | 591,941.00 |
| Jun 30, 2021 | 369,792.00 |